Luye Pharma Group Ltd.
Clinical trials sponsored by Luye Pharma Group Ltd., explained in plain language.
A pharmaceutical company focused on innovative drugs and complex formulations.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill combo aims to tackle Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis study tests a new oral drug, LPM6690176, added to standard chemotherapy and bevacizumab for people with a specific type of advanced colorectal cancer (RAS mutation). The first part finds the safest dose, and the second part compares the new combo against standard treatment a…
Phase: PHASE1, PHASE2 • Sponsor: Luye Pharma Group Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New pill aims to quiet Schizophrenia's voices
Symptom relief Not yet recruitingThis study tests an experimental drug called LY03020 in 160 adults with schizophrenia who are currently having severe symptoms (acute psychosis). Half will get the drug and half a placebo, and neither the patients nor the doctors will know who gets what. The main goal is to see i…
Phase: PHASE2 • Sponsor: Luye Pharma Group Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Radioactive pill tested in healthy men to map huntington Drug's path
Knowledge-focused Not yet recruitingThis early-stage study will give 8 healthy men a single radioactive dose of LPM3770164, a drug being developed for Huntington disease. Researchers will measure how much of the drug is recovered in urine and stool, and identify its breakdown products. The goal is to understand how…
Phase: PHASE1 • Sponsor: Luye Pharma Group Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC